CYCN supply chain intelligence for Cyclerion Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MEDSTEER-SAS | MEDSTEER-SAS | 90% | Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7 … |
| TISENTO-THERAPEUTICS-HOLDINGS-INC | TISENTO-THERAPEUTICS-HOLDINGS-INC | 90% | the shares of common stock of Tisento Therapeutics Holdings, Inc. that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement |
| JNJ | Johnson & Johnson | 72% | rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from JNJ grap… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY grap… |
| LLY | Eli Lilly and Company | 72% | rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p… |
| ORANY | ORANY | 72% | rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulator… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OPTIONEE | OPTIONEE | 90% | On July 22, 2024, we entered into the Option Agreement with the Optionee, which the Optionee had the Option to enter into an exclusive license to olinciguat for human therapeutics, subject to certain… |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CYCN-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 23,490; ownership 0.60%; value $36,409; as of 2025-12-31. |
| CYCN-OWNER-XTX-TOPCO-LTD | Xtx Topco Ltd | 95% | 13F/ownership overlay lists Xtx Topco Ltd; shares held 10,027; ownership 0.26%; value $15,541; as of 2025-12-31. |
| CYCN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 43,302; ownership 1.10%; value $67,118; as of 2025-12-31. |
| CYCN-OWNER-TWO-SIGMA-INVESTMENTS-LP | Two Sigma Investments, LP | 95% | 13F/ownership overlay lists Two Sigma Investments, LP; shares held 41,555; ownership 1.06%; value $64,410; as of 2025-12-31. |
| CYCN-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 16,797; ownership 0.43%; value $26,035; as of 2025-12-31. |
| CYCN-OWNER-FMR-LLC | FMR, LLC | 95% | 13F/ownership overlay lists FMR, LLC; shares held 4,740; ownership 0.12%; value $7,346; as of 2025-12-31. |
| CYCN-OWNER-SIREN-L-L-C | Siren, L.L.C. | 95% | 13F/ownership overlay lists Siren, L.L.C.; shares held 115,603; ownership 2.95%; value $179,184; as of 2025-12-31. |
| CYCN-OWNER-CITIGROUP-INC | Citigroup Inc. | 95% | 13F/ownership overlay lists Citigroup Inc.; shares held 8,204; ownership 0.21%; value $12,716; as of 2025-12-31. |
| CYCN-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC | Tower Research Capital LLC (TRC) | 95% | 13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 3,154; ownership 0.08%; value $4,888; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| JAGX | Jaguar Health, Inc. | 100.00 | 2 | |
| NEUP | Neuphoria Therapeutics Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['supplier'] |
| CVRX | CVRx, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| DARE | Daré Bioscience, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 |